Earlier Detection of Organ Rejection
CAP review outlines how donor-derived DNA assays can support earlier, less invasive detection of graft injury
-
1
Donor-derived cell-free DNA testing detects organ transplant injury earlier than conventional methods.
-
2
Rising levels of donor-derived cell-free DNA indicate graft injury, often preceding serum chemistry changes.
-
3
Next-generation sequencing and droplet digital PCR are the two main analytical approaches for dd-cfDNA.
-
4
Clinical applications of dd-cfDNA are well-established in kidney and heart transplantation.
-
5
dd-cfDNA testing represents a paradigm shift in transplant diagnostics, enabling personalized surveillance strategies.
